Stick With Allopurinol Instead of Febuxostat for Most Chronic Gout Patients

September 2018

Please see the February 2019 FDA advisory concerning the increased risk of death with Uloric (Febuxostat).

You'll hear about an advocacy group pushing for withdrawal of the gout med febuxostat (Uloric)...due to concerns it increases mortality.

We know patients with gout are already at elevated CV risk.

Early studies signaled a higher risk of CV events in patients on febuxostat compared to allopurinol...so FDA required a safety trial.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Recalls Be Ready to Prescribe Alternatives to Valsartan
Diabetes Expect to Hear About Renal Protection With Newer Diabetes Meds
Cardiology Consider the Pros and Cons of the ACC/AHA CV Risk Estimator
Gout Stick With Allopurinol Instead of Febuxostat for Most Chronic Gout Patients
Cannabinoids Be Prepared With Answers About Cannabidiol
Antibiotics More Warnings Will Further Limit Quinolone Use
Diabetes & Endocrinology Use a Stepwise Approach to Treat Hirsutism
Lice Sort Through Head Lice Treatments
Menopause Watch for Imvexxy, a New Low-Dose Vaginal Estrogen
Substance Use Disorder Think of Lucemyra as Similar to Clonidine for Opioid Withdrawal
Antibiotics Don't Expect the Antibiotic Plazomicin to Be Added to Your Hospital Formulary
Bites & Stings Know the Difference Between CroFab and the New Snakebite Antivenom Anavip